Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)

计划入组 10 人 · 首次发布于 2026 年 7 月 28 日

Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass

计划入组 20 人 · 首次发布于 2025 年 7 月 22 日

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

计划入组 121 人 · 首次发布于 2023 年 6 月 18 日

autologous tissue-engineered skin

COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin equivalent graft

Human acellular vessel (Humacyte)

Tissue Genesis

United States

Tissue Repair Ltd

Laser Tissue Welding, Inc.

United States

Humacyte Plans Q4 IND Filing for Coronary Tissue Engineered Vessel Following Promising Primate Study

Humacyte Secures $77.5 Million Credit Facility to Support Bioengineered Tissue Platform Expansion

Humacyte Secures Patent Protection for Bioengineered Esophagus Through 2041